NCT07639047: An Initial Evaluation of AN8025 in Solid Tumors

Summary

The goal of this clinical trial is to determine the appropriate dose of AN8025 for use in the treatment of advanced solid tumors. This study will be conducted in in adults \>18 years of age. The main questions to answer: 1. Determine which dose level of AN8025 is safe and tolerability in participants with advanced solid tumors 2. To determine the maximum tolerated of AN8025 for future testing. Participants will visit their study site in 3 week cycles, during which they will be under go treatment with AN8025 and visit their clinical site during each cycle for check ups and testing.

Timeline

Start: 2025-11-01
Primary completion: 2027-07
Completion: 2028-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AN8025	Protein / enzyme biologic	—	Intravenous

Indications

No indication recorded.